20102020 Apsis Therapeutics, Ltd. All rights reserved.

Our Technologies



bcProtideTM is a nucleoside analogue prodrug technology developed by APSIS for better efficacies, selective cellular delivery, and low toxicities of metabolizing intermediates and byproducts.






PurSelecTM is a technology developed by APSIS for regiospecific and stereoselective alkylation and glycosylation for library synthesis of purine nucleoside analogues.





APSIS claims a technology for library synthesis of nucleoside analogue triphosphates.






APSIS develops oligonucleotide-protein gene cleaving complexes (Engineered CRISPR-Cas9-lgRNA) and delivery technologies targeting viral DNAs for curing latent and/or chronic viral infections.